Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape – H2 2018

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Stimulant Abuse Deterrents: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, H2 2018

  • 186 Pages | 20-Jan-19 | Format:PDF | Last Updated: 20-Jan-19
  • GervanoRA’s pipeline analysis and opportunity assessment report “Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape – H2 2018” analyzed and assessed Stimulant Addiction (Cocaine and Methamphetamine) Market Overview by considering the global scenarios, epidemiology and proposed treatments for the Stimulant Addiction. The report also provides information related to Stimulant Abuse and Deterrence, factors affecting, treatments and impact on Health, Social and Economy through Stimulant Abuse. The Report also focuses on the global trends, recent developments and technologies like the formulation strategies and formulation technologies.For a good understanding about the report we have provided the Pipeline Analysis for Cocaine and Methamphetamine Drug Abuse Deterrent and Stimulant Drug Abuse Deterrent. We have in turn segmented the Chapter with respect to the Highest Stage of development, Geography, Route of Administration, Drug Class and Mechanism of Action. Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Unmet needs and Opportunities
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Estimated Pipeline Drug Approval Time lines
    • Clinical Trials Summary
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)
    • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.

  • TABLE OF CONTENTS
    1. INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2. EXECUTIVE SUMMARY
    2.1. REPORTS MAJOR FINDINGS
    2.2. KEY PIPELINE EVENTS 2018 TO 2034
    3. STIMULANT ADDICTION (COCAINE & METHAMPHETAMINE) MARKET OVERVIEW
    3.1. STIMULANT ADDICTION OVERVIEW
    3.2. STIMULANT ADDICTION GLOBAL SCENARIOS
    3.3. STIMULANT ADDICTION EPIDEMIOLOGY
    3.4. EPIDEMIOLOGY FORECAST
    3.4.1. FORECAST METHODOLOGY AND ASSUMPTION
    3.4.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
    3.5. STIMULANT ADDICTION PROPOSED TREATMENTS
    4. STIMULANT ABUSE OVERVIEW
    4.1. STIMULANT ABUSE AND DETERRENCE
    4.2. FACTORS AFFECTING ON STIMULANT ABUSE
    4.3. EFFECTS AND SYMPTOMS OF STIMULANT ABUSE
    4.4. CURRENT TREATMENTS OF STIMULANT ABUSE
    4.5. STIMULANT ABUSE – IMPACT ON HEALTH, SOCIAL AND ECONOMY
    5. ABUSE DETERRENT DEALS OVERVIEW
    5.1. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    5.1.1. COLLABORATION AGREEMENTS
    5.1.2. LICENSING AGREEMENTS
    5.1.3. TERMINATION AGREEMENTS AND SETTLEMENTS
    5.1.4. FUNDING & CONTRACTS
    5.1.5. PARTNERSHIPS
    5.1.6. ACQUISITIONS
    6. STIMULANT ABUSE DETERRENTS-RECENT DEVELOPMENTS AND TECHNOLOGIES
    6.1. STIMULANT ABUSE DETERRENT FORMULATION STRATEGIES
    6.2. STIMULANT ABUSE DETERRENT FORMULATION TECHNOLOGIES
    6.3. INTERNATIONAL GUIDELINES FOR ABUSABLE SUBSTANCES
    6.4. UNMET MEDICAL NEEDS AND GAPS IN THE TREATMENT OF STIMULANT ABUSE
    6.5. STIMULANT ABUSE GLOBAL TRENDS AND REGULATORY DEVELOPMENTS
    6.6. LIMITATIONS OF STIMULANT ABUSE DETERRENT FORMULATIONS
    7. PIPELINE ANALYSIS OF COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT
    7.1. THERAPEUTICS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT
    7.1.1. PHASE II MOLECULES
    7.1.2. PHASE I MOLECULES
    7.1.3. PRECLINICAL MOLECULES
    7.1.4. EARLY R&D MOLECULES
    7.1.5. INACTIVE MOLECULES
    7.2. PIPELINE ANALYSIS BY GEOGRAPHY
    7.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    7.4. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES
    8. PIPELINE ANALYSIS OF STIMULANT DRUG ABUSE DETERRENT
    8.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    8.1.1. PRE-REGISTRATION (FILED) MOLECULES
    8.1.2. PHASE III MOLECULES
    8.1.3. PHASE II MOLECULES
    8.1.4. PHASE I MOLECULES
    8.1.5. PRECLINICAL MOLECULES
    8.1.6. EARLY R&D (DISCOVERY) MOLECULES
    8.2. PIPELINE ANALYSIS BY GEOGRAPHY
    8.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    8.4. PIPELINE ANALYSIS BY DRUG CLASS
    8.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    8.6. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES
    9. ESTIMATED DRUG APPROVAL TIMELINES
    9.1. METHODOLOGY
    9.2. STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS
    9.2.1. UNITED STATES (FDA) ESTIMATIONS
    9.2.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS
    9.3. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS
    9.3.1. UNITED STATES (FDA) ESTIMATIONS
    9.3.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS
    10. CLINICAL TRIAL SUMMARY
    10.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT
    10.1.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    10.1.2. ONGOING CLINICAL TRIALS SUMMARY
    10.1.3. PLANNED CLINICAL TRIAL SUMMARY
    10.1.4. RECENTLY COMPLETED CLINICAL TRIALS
    10.2. STIMULANT DRUG ABUSE DETERRENT
    10.2.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS
    10.2.2. PLANNED CLINICAL TRIAL SUMMARY
    10.2.3. RECENTLY COMPLETED TRIALS
    10.3. WITHDRAWN AND DISCONTINUED PROJECTS
    11. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    11.1. EMERGING COMPANIES
    11.2. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS AND MILESTONES
    11.2.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EMERGING COMPANIES
    11.2.2. STIMULANT DRUG ABUSE DETERRENT EMERGING COMPANIES
    11.3. UNIVERSITIES AND INSTITUTES
    12. ABBREVIATIONS

    LIST OF TABLES
    TABLE 1: METHAMPHETAMINE V/S COCAINE
    TABLE 2: ILLICIT DRUG USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
    TABLE 3: STIMULANT USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
    TABLE 4: COCAINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
    TABLE 5: METHAMPHETAMINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)
    TABLE 6: COLLABORATION AGREEMENTS, 2000-2018
    TABLE 7: LICENSING AGREEMENTS, 2013-2018
    TABLE 8: TERMINATION AGREEMENTS
    TABLE 9: FUNDING AND CONTRACTS
    TABLE 10: PARTNERSHIPS DEALS
    TABLE 11: ACQUISITION DEALS
    TABLE 12: STAGE OF DEVELOPMENT V/S FORMULATION STRATEGIES
    TABLE 13: MOLECULES BELONGING TO TYPE 3 FORMULATION STRATEGY
    TABLE 14: MOLECULES BELONGING TO TYPE 2 FORMULATION STRATEGY
    TABLE 15: MOLECULE BELONGING TO TYPE 1 FORMULATION STRATEGY
    TABLE 16: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE II PIPELINE MOLECULES
    TABLE 17: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE I PIPELINE MOLECULES
    TABLE 18: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PRECLINICAL STAGE PIPELINE MOLECULES
    TABLE 19: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EARLY R&D PIPELINE MOLECULES
    TABLE 20: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT INACTIVE PIPELINE MOLECULES
    TABLE 21: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    TABLE 22: PRE-REGISTRATION (FILED) MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
    TABLE 23: PHASE III MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
    TABLE 24: PHASE II MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
    TABLE 25: PHASE I MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
    TABLE 26: PRECLINICAL MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
    TABLE 27: EARLY R&D MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE
    TABLE 28: LIST OF COMPANIES WITH PIPELINE MOLECULES BY STAGE OF DEVELOPMENT
    TABLE 29: LIST OF UNIVERSITIES AND INSTITUTES WITH PIPELINE MOLECULES
    TABLE 30: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL
    TABLE 31: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL
    TABLE 32: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL
    TABLE 33: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL
    TABLE 34: MN-166 (IBUDILAST) PHASE II CLINICAL TRIAL STUDY DESIGN
    TABLE 35: SYN117 (NEPICASTAT) PHASE II CLINICAL TRIAL STUDY DESIGN
    TABLE 36: MEASURED VALUE FOR PRIMARY MEASURE- ABSTINENCE
    TABLE 37: MEASURED VALUE FOR SECONDARY MEASURE- REDUCTION IN USE
    TABLE 38: ONGOING PHASE II CLINICAL TRIALS
    TABLE 39: ORADUR-METHYLPHENIDATE ER PHASE III CLINICAL TRIALS STUDY DESIGN
    TABLE 40: HLD200 PHASE III CLINICAL TRIALS STUDY DESIGN
    TABLE 41: HLD200 SECOND PIVOTAL PHASE III CLINICAL TRIALS STUDY DESIGN
    TABLE 42: HLD100 PHASE II TRIAL RESULTS
    TABLE 43: RBP-8000 PHASE II CLINICAL TRIALS STUDY DESIGN
    TABLE 44: LIST OF UNIVERSITIES AND INSTITUTES

    LIST OF FIGURES
    FIGURE 1: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2021-2023
    FIGURE 2: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2024-2028
    FIGURE 3: KEY PIPELINE EVENTS, STIMULANT DRUG ABUSE DETERRENT, 2018-2034
    FIGURE 4: COCAINE USE TRENDS, US, 2002-2016
    FIGURE 5: COCAINE USE TRENDS, CANADA, 2004-2009
    FIGURE 6: RELATIVE COMPARISION IN PREVALENCE OF COCAINE AND METHAMPHETAMINE DRUG USE, 2009-2013
    FIGURE 7: COMPARISION OF COCAINE USERS BY AGE GROUP, 2015-2016
    FIGURE 8: COMPARISION OF METHAMPHETAMINE USERS BY AGE GROUP, 2015-2016
    FIGURE 9: COCAINE USE, 2015-2016
    FIGURE 10: ILLICIT DRUG USERS, US, 2010-2016
    FIGURE 11: PREVALENCE OF COCAINE USE, AGE GROUP, CANADA, 2008-2015
    FIGURE 12: ILLICIT DRUG USERS AGED 12 AND OLDER; FORECAST (2017-2025)
    FIGURE 13: STIMULANT USERS AGED 12 AND OLDER; FORECAST (2017-2025)
    FIGURE 14: COCAINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)
    FIGURE 15: METHAMPHETAMINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)
    FIGURE 16: PHARMACOLOGICAL TREATMENT OPTIONS FOR STIMULANT ADDICTION
    FIGURE 17: DEAL ACTIVITY, CNS STIMULANTS AND OPIOIDS
    FIGURE 18: STRATEGIES FOR STIMULANT ABUSE DETERRENT FORMULATION
    FIGURE 19: ANNUAL PREVALENCE AND NUMBER OF ILLICIT DRUG USERS AT THE GLOBAL LEVEL, 2010
    FIGURE 20: ILLICIT DRUG USE AT THE GLOBAL LEVEL, 2008
    FIGURE 21: COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015
    FIGURE 22: DALY’S COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015
    FIGURE 23: ANNUAL PREVALENCE OF THE USE OF COCAINE AND METHAMPHETAMINE BY REGION AND GLOBALLY, 2015
    FIGURE 24: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    FIGURE 25: STIMULANT DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT- COMPANIES
    FIGURE 26: STIMULANT DRUG DETERRENT PIPELINE ANALYSIS BY GEOGRAPHY

Pricing

Individual Pricing $2500

Corporate Pricing $2500

Enterprise Pricing $2500

(We are offering all the above license types for a single price!!)